ARLINGTON HEIGHTS, IL — In a move designed to bridge the gap between regulatory rigor and clinical practicality, the Breast Surgery Collaborative Community (BSCC) has officially submitted a proposal to the U.S. Food and Drug Administration (FDA) to overhaul the current Breast Implant Patient Decision Checklist. This initiative, now open for public comment, marks a pivotal moment in the ongoing effort to refine informed consent processes for patients undergoing breast augmentation or reconstruction.
The BSCC, a multi-stakeholder coalition consisting of surgeons, patient advocates, and industry representatives, is seeking to transform a document that many in the medical community have found cumbersome since its inception in 2022. By prioritizing clarity, brevity, and actionable information, the group aims to foster a more meaningful dialogue between patients and physicians.
The Genesis of the Checklist: A Chronology of Clinical Evolution
To understand the necessity of this proposal, one must look at the regulatory trajectory of breast implant safety.
2019–2021: The Regulatory Pivot
Following years of advocacy regarding the safety profile of breast implants—specifically regarding Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Breast Implant Illness (BII)—the FDA began exploring new ways to enhance informed consent. The goal was to ensure that patients understood the life-long risks associated with surgical breast devices.
2022: Implementation and Growing Pains
In 2022, the FDA officially mandated the use of a Patient Decision Checklist. While the medical community largely welcomed the intent behind the document, the execution met with immediate friction. Clinicians reported that the length and density of the form often overwhelmed patients during consultation sessions. Rather than facilitating a conversation, the checklist occasionally became a hurdle, consuming valuable time that could have been spent on personalized surgical planning and deeper patient education.
2023–2024: The BSCC Consensus Effort
Recognizing the disconnect, the BSCC—an organization operating under the FDA’s "collaborative community" framework—initiated a comprehensive review. Over the past two years, the group brought together a diverse panel of board-certified plastic surgeons, patient advocates from groups like the Breast Implant Safety Alliance (BISA), and representatives from major implant manufacturers. The objective was clear: create a document that retains all necessary safety warnings while being concise enough to serve as a genuine "decision-making tool" rather than a mere administrative formality.
Addressing the "Paperwork Burden": Why Clarity Matters
The core critique of the 2022 FDA checklist was its lack of "practical usefulness." In the high-stakes environment of a pre-operative consultation, patients are often managing significant emotional and physical stress. A document that is overly technical or excessively long can lead to "information overload," where patients may sign off on risks without fully internalizing them.
The proposed revision focuses on three pillars:
- Conciseness: Reducing redundant language without sacrificing the critical safety disclosures required by law.
- Accessibility: Utilizing plain language that is easily understood by patients from various educational backgrounds.
- Actionability: Organizing the information in a way that prompts specific, high-value questions from the patient to the surgeon, thereby strengthening the shared decision-making model.
Supporting Data and the Shared Decision-Making Model
The BSCC’s proposal is rooted in the philosophy of "shared decision-making." In modern medicine, the physician-patient relationship is no longer a top-down directive; it is a partnership. However, for that partnership to function, the information provided must be digestible.
Current data in medical education suggests that patient comprehension significantly drops when consent documents exceed a certain page count or readability score. By streamlining the checklist, the BSCC hopes to increase the likelihood that patients will actually read the document in its entirety and engage in a dialogue about the specific risks, such as rupture, capsular contracture, and the potential need for future revision surgeries.
The collaborative nature of the BSCC is its strongest asset. By including patient advocates like Jennifer Cook and clinical experts like Dr. William P. Adams Jr. in the drafting process, the group has ensured that the checklist addresses the real-world anxieties of patients while respecting the clinical reality of surgical practice.
Official Responses and the Public Docket
The BSCC has made it clear that they do not view this proposal as a static final draft, but as a living document that requires the "wisdom of the crowd." By submitting the proposal to the FDA’s public docket, the BSCC is inviting the broader community to weigh in.
How to Participate:
The FDA has opened a formal comment period, and the BSCC is urging all stakeholders—patients, surgeons, nurses, and researchers—to review the proposal.
- Submission Link: Regulations.gov (Docket: FDA-2019-D-4467-1386)
- Deadline: December 1, 2026.
- Important: To ensure your feedback is associated with the BSCC’s specific initiative, please include the tracking number: mt7-xgl2-2crx.
Implications for the Future of Plastic Surgery
If adopted, the revised checklist could serve as a model for other medical device categories. The "Collaborative Community" framework—where the FDA, private industry, and patient advocates work in tandem—has proven to be a highly effective method for refining regulatory policy.
Impact on Surgeons
For plastic surgeons, a more streamlined checklist means more time to focus on the nuances of the patient’s goals and medical history. It reduces the administrative burden while potentially increasing the quality of the informed consent process, which serves as a vital safeguard against misunderstandings and future litigation.
Impact on Patients
For patients, the primary benefit is empowerment. A clearer, more concise document helps the patient feel more in control of their surgical journey. It allows them to focus on the essential risks and benefits, rather than getting lost in dense regulatory jargon.
Impact on Regulatory Policy
The FDA’s willingness to entertain these revisions signals a maturing of the regulatory environment. It suggests that the agency is listening to the challenges faced on the "front lines" of medicine. If this collaborative effort results in a more effective tool, it could set a precedent for how the FDA manages patient-facing documentation in other fields, such as orthopedics or cardiology.
About the Breast Surgery Collaborative Community (BSCC)
The BSCC is more than just a committee; it is a vital forum for the intersection of clinical care and regulatory oversight. Comprised of representatives from the American Society of Plastic Surgeons (ASPS), The Aesthetic Society, The Plastic Surgery Foundation (PSF), and various patient advocacy groups, the organization is committed to a culture of safety.
The inclusion of manufacturers—such as Mentor Worldwide, Establishment Labs, and Sientra—ensures that the technical realities of device safety are balanced with the practicalities of patient education. By operating under the FDA’s collaborative community framework, the BSCC creates a continuous feedback loop that allows the medical community to adapt to new data and patient concerns in real-time.
Leadership and Membership
The strength of the BSCC lies in its diverse roster. The collaborative effort is guided by a blend of clinical leadership and patient-centric oversight:
- Clinical Leadership: Including Dr. William P. Adams Jr., Dr. Scot B. Glasberg, and Dr. George Chatson, among others.
- Patient Advocacy: Including Jennifer Cook, Amanda Hynum, and Cynthia Johnson, RN, who bring the essential perspective of the patient experience.
- Regulatory Liaison: Including representatives from major manufacturers like Sheryl Robinson-Collins and Margie Rose.
As the industry moves toward a future of increased transparency and improved patient outcomes, the work of the BSCC stands as a testament to the power of cooperation. The path forward involves listening, refining, and, ultimately, prioritizing the patient’s right to clear and concise information.
The public comment period is now open, and the medical community awaits the next step in this critical evolution of patient safety.
About the Author
